Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace.

Date publication

septembre 2015

Journal

Drugs - real world outcomes

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VELTEN Michel

Tous les auteurs :
Beck M, Velten M, Rybarczyk-Vigouret MC, Covassin J, Sordet C, Michel B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27747567

Résumé

The economic burden linked to rheumatoid arthritis (RA) has greatly increased since the inclusion of biotherapies in the therapeutic arsenal.

Référence

Drugs Real World Outcomes. 2015 Sep;2(3):205-215